ClinicalTrials.gg
Active, not recruitingNCT05097287ATLASUpdated Apr 16, 2026

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

A Phase 4 interventional study of Dupilumab and Placebo in Asthma, sponsored by Sanofi. Active, not recruiting at 249 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,339
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
3rd of 31
1,339 · median 120
Started
2021
with 2 others
Phase 4
14 of 31
5 open now
Primary completion
2027-03
later than 5 of 11 live
Registered
22nd of 31
by date
Lead sponsor
15 of 31
Sanofi

Among the 31 studies testing dupilumab in Asthma, this one is the 3rd largest by enrollment, is one of 3 that started in 2021, is one of 14 in phase 4, reaches primary completion later than 5 of the 11 other live ones, and was the 22nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma.

The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be at least 18 (or the legal age of consent in the jurisdiction in which the study is taking place) years of age inclusive, at the time of signing the .
  • Patients with a physician diagnosis of asthma (according to Global Initiative for Asthma (GINA) 2021) for ≥12 months
  • Treatment with medium to high dose inhaled (ICS) in combination with a second controller (eg, long-acting beta-2 adrenergic receptor agonists (LABA), leukotriene receptor antagonists (LTRA) with a stable dose ≥1 month prior to Visit 1. Patients requiring a third controller for their asthma will be considered eligible for this study, and it should also be on stable dose ≥1 month prior to Visit 1. Patients requiring an additional controller as a fourth controller (Montelukast) for another type 2 comorbid condition such as allergic rhinitis will be considered eligible for this study, and should be on a stable dose for ≥1 month prior to Visit 1.
  • Pre-bronchodilator (FEV1) ≤ 80% of predicted normal for adults at Visits 1 and 2, prior to randomization
  • Asthma Control Questionnaire 5-question version (ACQ-5) score ≥1.5 at Visits 1 and 2, prior to randomization.
  • Variable airflow obstruction as documented by one or more of the following (at least 1 needs to be met):

    i) Positive reversibility test: ≥12% and 200 mL improvement in FEV1 after SABA administration prior to randomization, or documented in the 24 months prior to Visit 1. OR, ii) Positive bronchial challenge test: fall in FEV1 of ≥20% with standard doses of methacholine, or ≥15% with standardized hyperventilation, hypertonic saline or mannitol challenge prior to randomization or documented in the 24 months prior to Visit 1 OR, iii) Average daily diurnal Peak flow variability of >10% over a 2-week period, documented in the past 24 months prior to Screening Visit 1. OR, iv) Airflow variability in clinic FEV1 >12% and 200 mL between visits outside of respiratory infections, documented in the past 24 months prior to Screening Visit 1. OR v) FEV1 increases by more than 12% and 200mL from baseline after 4 weeks of anti-inflammatory treatment.

  • Reversibility test: Three attempts may be made during the Screening Period until the Baseline visit to meet the qualifying criteria for reversibility. This is only required if reversibility or other evidence of expiratory airflow limitation eligibility criteria was not performed within 24 months prior to Visit 1.
  • FeNO ≥35 ppb at Visit 2, prior to randomization.
  • History of ≥1 severe exacerbation(s) in the previous year before Visit1 defined as a deterioration of asthma requiring:

    i) Use of systemic corticosteroids for ≥3 days; or ii) Hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • History or clinical evidence of (COPD) including Asthma-COPD Overlap Syndrome (ACOS) or any other significant lung disease (eg, emphysema, lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome).
  • Severe asthma exacerbation requiring treatment with systemic (SCS) in the past month before visit 1 or during the screening period.
  • Current acute bronchospasm or status asthmaticus.
  • Diagnosed pulmonary (other than asthma) or systemic disease associated with elevated peripheral eosinophil counts.
  • Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study. Examples include, but are not limited to, participants with short , uncontrolled diabetes, cardiovascular conditions, severe renal conditions (eg, participants on dialysis), or other severe endocrinological, gastrointestinal, metabolic, pulmonary, psychiatric, or lymphatic diseases. The specific justification for participants excluded under this criterion will be noted in the study documents (chart notes, case report forms [CRFs], etc).
  • Patients with active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history of incompletely treated TB will be excluded from the study unless it is well documented by a specialist that the participant has been adequately treated and can now start treatment with a biologic agent, in the medical judgment of the Investigator and/or infectious disease specialist. Tuberculosis testing will be performed on a country by country basis, according to local guidelines if required by regulatory authorities or ethics boards, or if TB is suspected by the investigator
  • Known or suspected immunodeficiency, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune-compromised status, as judged by the Investigator.
  • Active or history of malignancy within 5 years before Visit 1 (screening visit), except completely treated in situ carcinoma of the cervix and completely treated and resolved non squamous or basal cell carcinoma of the skin.
  • Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antifungals or receiving only symptomatic treatment (e.g. influenza or COVID-19) within 2 weeks before the screening visit (Visit 1) or during the screening period.
  • History of (HIV) infection or positive HIV 1/2 serology at Visit 1 (screening visit).
  • Diagnosed with, suspected of, or at high risk of endoparasitic infection, and/or use of antiparasitic drugs within 2 weeks before Visit 1 (screening visit) or during the screening and run-in period
  • Current smoker (cigarette or e-cigarette) or cessation of smoking within 6 months prior to Visit 1.
  • Previous smoker with a smoking history >10 pack-years.
  • History of systemic or anaphylaxis to dupilumab or any other biologic therapy, including any .
  • Any biologic therapy (including experimental treatments and dupilumab) or any other biologic therapy//immunomodulators within 4 weeks prior to V1 or 5 half-lives, whichever is longer.
  • Treatment with a live (attenuated) vaccine within 4 weeks before Visit 1 (screening visit) or during the screening period.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,339 participants (actual)

Study arms

  • Experimental
    Dupilumab

    Dupilumab administered every 2 weeks (Q2W) after an initial loading dose (2 injections) on Day 1

    Drug: Dupilumab

  • Placebo comparator
    Placebo

    Matching placebo administered Q2W after an initial loading dose (2 injections) on Day 1

    Drug: Placebo

Interventions

  • solution for injection subcutaneous

  • DrugPlacebo

    solution for injection subcutaneous

06

What researchers measure

Primary outcomes

  1. Rate of change from week 8 to week 52 on post-BD FEV1 slope in FeNO population

    Rate of change from week 8 to week 52 on post-bronchodilator (BD) forced expiratory volume in one second (FEV1) slope in FeNO population.

    Time frame: Week 8 to Week 52

Secondary outcomes

  1. Rate of change from week 8 to week 52 on post-BD FEV1 slope in the Total population

    Rate of change from week 8 to week 52 on post-BD FEV1 slope in the Total population.

    Time frame: Week 8 to Week 52

  2. Rate of change from week 8 to week 104 on post-BD FEV1 slope in the FeNO population

    Rate of change from week 8 to week 104 on post-BD FEV1 slope in the FeNO population.

    Time frame: Week 8 to Week 104

  3. Change from baseline to week 52 in pre-BD FEV1 in FeNO and Total populations

    Change from baseline to week 52 in pre-BD FEV1 in FeNO and Total populations.

    Time frame: Baseline to Week 52

  4. Change from baseline to week 52 in post-BD FEV1 in FeNO and Total populations

    Change from baseline to week 52 in post-BD FEV1 in FeNO and Total populations.

    Time frame: Baseline to Week 52

  5. Annualized severe exacerbation rate during the 52-week period in FeNO and Total populations

    Exacerbation defined as a deterioration of asthma requiring use of systemic corticosteroids for ≥3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids.

    Time frame: Baseline to Week 52

  6. Change from baseline to week 52 in fractional exhaled nitric oxide (FeNO) levels in FeNO and Total populations

    Change from baseline to week 52 in FeNO levels in FeNO and Total populations.

    Time frame: Baseline to Week 52

  7. Change from baseline to week 52 in Asthma Control Questionnaire 7 items (ACQ-7) in FeNO and Total populations

    ACQ-7 was designed to measure both the adequacy of asthma control and change in asthma control. A global score ranges between 0 (totally controlled) and 6 (severely uncontrolled). Higher score indicates lower asthma control.

    Time frame: Baseline to Week 52

  8. Change from baseline to week 52 in pre-BD FEV1 % predicted in FeNO and Total populations

    Change from baseline to week 52 in pre-BD FEV1 % predicted in FeNO and Total populations.

    Time frame: Baseline to Week 52

  9. Change from baseline to week 52 in Forced Vital Capacity (FVC) in FeNO and Total populations

    Change from baseline to week 52 in FVC in FeNO and Total populations.

    Time frame: Baseline to Week 52

  10. Rate of change from week 8 to week 104 on post-BD FEV1 slope in Total Population

    Rate of change from week 8 to week 104 on post-BD FEV1 slope in Total Population.

    Time frame: Week 8 to Week 104

  11. Change from baseline to week 104 in pre-BD FEV1 in FeNO and Total populations

    Change from baseline to week 104 in pre-BD FEV1 in FeNO and Total populations.

    Time frame: Baseline to Week 104

  12. Change from baseline to week 104 in post-BD FEV1 in FeNO and Total populations

    Change from baseline to week 104 in post-BD FEV1 in FeNO and Total populations.

    Time frame: Baseline to Week 104

  13. Annualized severe exacerbation rate during the 104-week period in FeNO and Total populations

    Exacerbation defined as a deterioration of asthma requiring use of systemic corticosteroids for ≥3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids.

    Time frame: Baseline to Week 104

  14. Change from baseline to week 104 in FeNO levels in FeNO and Total populations

    Change from baseline to week 104 in FeNO levels in FeNO and Total populations.

    Time frame: Baseline to Week 104

  15. Change from baseline to week 104 in ACQ-7 in FeNO and Total populations

    ACQ-7 was designed to measure both the adequacy of asthma control and change in asthma control. A global score ranges between 0 (totally controlled) and 6 (severely uncontrolled). Higher score indicates lower asthma control.

    Time frame: Baseline to Week 104

  16. Change from baseline to week 104 in pre-BD FEV1 % predicted in FeNO and Total populations

    Change from baseline to week 104 in pre-BD FEV1 % predicted in FeNO and Total populations.

    Time frame: Baseline to Week 104

  17. Change from baseline to week 104 FVC in FeNO and Total populations

    Change from baseline to week 104 FVC in FeNO and Total populations.

    Time frame: Baseline to Week 104

  18. Change from baseline to week 52 in Asthma Quality Of Life Questionnaire with Standardized Activities (AQLQ(S)) in FeNO and Total populations

    The AQLQ (S) was designed as a self-administered patient reported outcome to measure the functional impairments that are most troublesome to patients as a result of their asthma. A global score is calculated ranging from 1 to 7. Higher scores indicate better quality of life.

    Time frame: Baseline to Week 52

  19. Change from baseline to week 104 in AQLQ(S) in FeNO and Total populations

    The AQLQ (S) was designed as a self-administered patient reported outcome to measure the functional impairments that are most troublesome to patients as a result of their asthma. A global score is calculated ranging from 1 to 7. Higher scores indicate better quality of life.

    Time frame: Baseline to Week 104

  20. Rate of change from week 8 to week 156 on post-BD FEV1 slope in FeNO and Total populations

    Rate of change from week 8 to week 156 on post-BD FEV1 slope in FeNO and Total populations.

    Time frame: Week 8 to Week 156

  21. Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Incidence of TEAEs and SAEs.

    Time frame: Baseline to Week 168

  22. Incidence of adverse events of special interest (AESIs)

    Incidence of AESIs.

    Time frame: Baseline to Week 168

07

Study locations

249 sites
  • Cullman Research Center- Site Number : 8400001
    Cullman, Alabama 35055, United States
  • Shoals Primary Care - Sheffield- Site Number : 8400015
    Sheffield, Alabama 35660, United States
  • Chandler Clinical Research Trials- Site Number : 8400147
    Chandler, Arizona 85224, United States
  • Pulmonary Associates - Deer Valley Office- Site Number : 8400155
    Phoenix, Arizona 85027, United States
  • Medical Advancement Center of Arizona (MACOA)- Site Number : 8400130
    Phoenix, Arizona 85051, United States
  • Del Sol Research Management - Tucson- Site Number : 8400017
    Tucson, Arizona 85715, United States
  • Kern Allergy and Medical Research- Site Number : 8400037
    Bakersfield, California 93301, United States
  • Vitality Clinical Research- Site Number : 8400142
    Beverly Hills, California 90211, United States
  • Ascada Research - Fullerton- Site Number : 8400076
    Fullerton, California 92835, United States
  • Allergy and Asthma Specialists Medical Group- Site Number : 8400162
    Huntington Beach, California 92647, United States
  • Newport Native MD- Site Number : 8400054
    Newport Beach, California 92663, United States
  • Prospective Research Innovations- Site Number : 8400131
    Rancho Cucamonga, California 91730, United States
  • Mercy Medical Group - Midtown- Site Number : 8400164
    Sacramento, California 95816, United States
  • Integrated Research of Inland- Site Number : 8400156
    Upland, California 91786, United States
  • Allianz Research Institute- Site Number : 8400018
    Westminster, California 92683, United States
  • Woodland Clinic - Woodland- Site Number : 8400171
    Woodland, California 95695, United States
  • Central Florida Pulmonary Group - Altamonte Springs- Site Number : 8400035
    Altamonte Springs, Florida 32701, United States
  • Florida Center for Allergy & Asthma Research- Site Number : 8400032
    Aventura, Florida 33180, United States
  • Beautiful Minds Clinical Research Center- Site Number : 8400141
    Cutler Bay, Florida 33157, United States
  • Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8400023
    DeBary, Florida 32713, United States
  • Florida Lung, Asthma and Sleep Specialists (FLASS) - Polynesian- Site Number : 8400098
    Kissimmee, Florida 34746, United States
  • Ivetmar Medical Group- Site Number : 8400063
    Miami, Florida 33155, United States
  • My Preferred Research- Site Number : 8400073
    Miami, Florida 33155, United States
  • Research Institute of South Florida- Site Number : 8400079
    Miami, Florida 33173, United States
  • Floridian Clinical Research - Miami Lakes- Site Number : 8400091
    Miami Lakes, Florida 33016, United States
  • Heuer M.D. Research- Site Number : 8400024
    Orlando, Florida 32819, United States
  • JSV Clinical Research- Site Number : 8400150
    Tampa, Florida 33634, United States
  • Appalachian Clinical Research- Site Number : 8400129
    Adairsville, Georgia 30103, United States
  • Alpha Clinical Research Group - Dunwoody- Site Number : 8400116
    Dunwoody, Georgia 30350, United States
  • Aeroallergy Research Laboratory- Site Number : 8400114
    Savannah, Georgia 31406, United States
  • Rush University Medical Center- Site Number : 8400146
    Chicago, Illinois 60612, United States
  • NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8400138
    Skokie, Illinois 60077, United States
  • Family Allergy & Asthma - Louisville - Goss Avenue- Site Number : 8400160
    Louisville, Kentucky 40217, United States
  • Allergy and Asthma Specialist- Site Number : 8400007
    Owensboro, Kentucky 42301, United States
  • Avant Research Associates - Crowley- Site Number : 8400117
    Crowley, Louisiana 70526, United States
  • Investigational Site Number : 3560016
    Houma, Louisiana 70360-4413, United States
  • Tandem Clinical Research - Metairie- Site Number : 8400163
    Metairie, Louisiana 70006, United States
  • Javara Privia Mid-Atlantic - Annapolis- Site Number : 8400087
    Annapolis, Maryland 21401, United States
  • Urgent Care Clinical Trials and KUR Research- Site Number : 8400169
    Columbia, Maryland 21045, United States
  • Chesapeake Clinical Research - White Marsh- Site Number : 8400119
    White Marsh, Maryland 21162, United States
  • Genesis Clinical Research - Fall River- Site Number : 8400050
    Fall River, Massachusetts 02723, United States
  • University of Michigan Health System - Ann Arbor- Site Number : 8400030
    Ann Arbor, Michigan 48109, United States
  • Revival Research Institute - Dearborn- Site Number : 8400097
    Dearborn, Michigan 48126, United States
  • Revive Research Institute - Lathrup Village- Site Number : 8400100
    Lathrup Village, Michigan 48076, United States
  • Romedica- Site Number : 8400043
    Rochester, Michigan 48307, United States
  • Great Lakes Research Institute Site Number : 8400111
    Southfield, Michigan 48075-5400, United States
  • Great Lakes Research Institute - Southfield- Site Number : 8400111
    Southfield, Michigan 48075, United States
  • Allergy & Immunology Associates of Ann Arbor- Site Number : 8400107
    Ypsilanti, Michigan 48197, United States
  • The Asthma and Allergy Center- Site Number : 8400055
    Bellevue, Nebraska 68123, United States
  • Jersey City Breathing Center: Elamir Mazhar- Site Number : 8400143
    Jersey City, New Jersey 07304, United States
  • Urban Health Plan- Site Number : 8400144
    The Bronx, New York 10459, United States
  • Clinical Research Of Gastonia- Site Number : 8400012
    Gastonia, North Carolina 28054, United States
  • Advanced Respiratory and Sleep Medicine - Huntersville- Site Number : 8400056
    Huntersville, North Carolina 28078, United States
  • Lapis Clinical Research - Mooresville- Site Number : 8400112
    Mooresville, North Carolina 28117, United States
  • Southeastern Research Center- Site Number : 8400153
    Winston-Salem, North Carolina 27103, United States
  • Asthma & Allergy Center - Toledo- Site Number : 8400051
    Toledo, Ohio 43617, United States
  • St. Luke's University Hospital- Site Number : 8400099
    Bethlehem, Pennsylvania 18015, United States
  • Temple University Hospital- Site Number : 8400038
    Philadelphia, Pennsylvania 19140, United States
  • Allergy & Clinical Immunology Associates Pittsburgh- Site Number : 8400042
    Pittsburgh, Pennsylvania 15241, United States
  • Bogan Sleep Consultants- Site Number : 8400102
    Columbia, South Carolina 29201, United States
  • Allergic Disease and Asthma Center (ADAC)- Site Number : 8400026
    Greenville, South Carolina 29607, United States
  • Main Street Physician's Care- Site Number : 8400077
    Little River, South Carolina 29566, United States
  • National Allergy and Asthma - North Charleston - Northside Drive- Site Number : 8400092
    North Charleston, South Carolina 29420, United States
  • Health Concepts- Site Number : 8400006
    Rapid City, South Dakota 57702, United States
  • REX Clinical Trials - Beaumont- Site Number : 8400135
    Beaumont, Texas 77701, United States
  • South Texas Medical Research Institute - TTS Research- Site Number : 8400009
    Boerne, Texas 78006, United States
  • Discovery Clinical Trials - Dallas- Site Number : 8400123
    Dallas, Texas 75225, United States
  • IntraCare- Site Number : 8400003
    Dallas, Texas 75254, United States
  • C & R Research Services - Houston- Site Number : 8400067
    Houston, Texas 77022, United States
  • Clear Brook Medical Associates- Site Number : 8400080
    Houston, Texas 77089, United States
  • Metroplex Pulmonary and Sleep Center- Site Number : 8400014
    McKinney, Texas 75069, United States
  • Andante Research- Site Number : 8400140
    San Antonio, Texas 78229, United States
  • DM Clinical Research - 710 Lawrence Street- Site Number : 8400103
    Tomball, Texas 77375, United States
  • Burke Internal Medicine and Research- Site Number : 8400170
    Burke, Virginia 22015, United States
  • University of Virginia- Site Number : 8400082
    Charlottesville, Virginia 22908, United States
  • Investigational Site Number : 0560002
    Brussels, 1200, Belgium
  • Investigational Site Number : 0560003
    Liège, 4000, Belgium
  • Associacao Proar- Site Number : 0760004
    Salvador, Estado de Bahia 40060-330, Brazil
  • Santa Casa de Misericordia de Belo Horizonte- Site Number : 0760006
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Health & Care - Consultancy, Research and HealthCare Management- Site Number : 0760010
    Belém, Pará 66095-055, Brazil
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760003
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760005
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Hospital Dia do Pulmão- Site Number : 0760002
    Blumenau, Santa Catarina 89030-101, Brazil
  • Clinica de Alergia Martti Antila- Site Number : 0760009
    Sorocaba, São Paulo 18040-425, Brazil
  • Hospital Alemao Oswaldo Cruz - São Paulo- Site Number : 0760007
    São Paulo, 01323-020, Brazil
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760008
    São Paulo, 05403-000, Brazil
  • Investigational Site Number : 1000005
    Dupnitsa, 2600, Bulgaria
  • Investigational Site Number : 1000012
    Plovdiv, 4023, Bulgaria
  • Investigational Site Number : 1000011
    Rousse, 7000, Bulgaria
  • Investigational Site Number : 1000002
    Sofia, 1233, Bulgaria
  • Investigational Site Number : 1000008
    Sofia, 1407, Bulgaria
  • Investigational Site Number : 1000009
    Sofia, 1431, Bulgaria
  • Investigational Site Number : 1000014
    Sofia, 1756, Bulgaria
  • Investigational Site Number : 1000013
    Vratsa, 3001, Bulgaria
  • Investigational Site Number : 1240028
    Calgary, Alberta T3B 0M3, Canada
  • Investigational Site Number : 1240020
    Kelowna, British Columbia V1W 3H5, Canada
  • Investigational Site Number : 1240022
    Vancouver, British Columbia V5Z 1M9, Canada
  • Investigational Site Number : 1240004
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Investigational Site Number : 1240010
    Moncton, New Brunswick E1G 5C4, Canada
  • Investigational Site Number : 1240015
    Ajax, Ontario L1S 2J5, Canada

Showing the first 100 of 249 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • De Prado Gomez L, Pavord I, Busse W, Brightling CE, Wechsler ME, Rabe KF, Zhang M, Xing J, Jacob-Nara JA, Rowe PJ. Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design. ERJ Open Res. 2023 Mar 6;9(2):00417-2022. doi: 10.1183/23120541.00417-2022. eCollection 2023 Mar. PubMed 36891077 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Mar 2027, 63 months after the start.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 63 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2021
First posted
Oct 28, 2021
StartActual
Dec 16, 2021
Primary completionEst.
Mar 16, 2027
CompletionEst.
Jun 8, 2029
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05097287
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 28, 2021
Start date
Dec 16, 2021
Primary completion
Mar 16, 2027 (estimated)
Completion
Jun 8, 2029 (estimated)
Last update
Apr 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion